Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Scientist II in the Translational Research team, within the Biology Department, you will: As a member of a cross-functional quantitative modeling group, collaborate with team members to develop, validate and refine physiologically-based PK (PBPK), quantitative systems pharmacology (QSP), and semi-mechanistic PK/PD models to support discovery and development-phase projects. Seek and apply innovative modeling approaches to understand tumor resistance to RAS(ON) inhibitors and build in silico models, propose mechanistic in vitro and in vivo experiments to test model assumptions and structure. Design and oversee in vivo and ex vivo studies (internally and via CROs), develop and maintain high-quality protocols and documentation, and present results at internal forums and scientific conferences.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree
Number of Employees
251-500 employees